You are on page 1of 4

India Destination

According to UNCTAD's World Investment Prospects Survey 2010-2012, India is the second-most attractive destination for FDI in the world. The Economy of India is the ninth largest in the world by nominal GDP and the third largest by purchasing power parity (PPP). Indias economy has strong fundamentals and is host to several eminent global corporate giants that are leaders in their respective fields. According to the Global Competitiveness Report 201011, India ranks at 51 among 139 countries. India ranks higher than many countries in key parameters such as market size (4th) and innovation (39th). India is among the worlds youngest nations with a median age of 25 years as compared to 43 in Japan and 36 in the US. In 2025, more than 55 per cent of the population would be of working age. India has better protection of Intellectual Property Rights, a well-structured banking & financial system, a strong judiciary and a qualified work force with English language skills. It is estimated that by about 2025 India will have 25 per cent of the worlds total workforce. The rural market represents the largest potential market in the country. Over 70% of Indias population residing in rural areas. A report by National Sample Survey Office (NSSO) has revealed that rural households' expenditure on durable goods has increased from 3.1 per cent (1987-88) to 4.8 per cent (2009-10), confirming that the expenditure on non-food items like durable goods has increased over the past few decades.

Economic Overview
Among the growing economic of the world India ranks second after China. The Countrys GDP has been growing at an average rate of 8.6% for the last five year. India's GDP grew at 8.5% in FY-2011. Due to high level of inflation and a tight monetary policy the GDP for FY 12 is forecasted to grow by 7.7%. As compare to the other countries, India has been and continues to be relatively insulated from external shocks due to its strong domestic consumption pattern. Consequently, India was relatively unaffected by the global recession, which affect the whole world in FY 09. India recorded a GDP growth rate of 6.8% during this period. Consumer spending in India is likely to grow nearly four times to touch US$ 3.6 trillion by 2020, driven by rising incomes and aspirations, widespread media proliferation and better physical reach across the country. Private domestic consumption accounts for more than 50% of the countrys GDP and is one of the key factor driving overseas investments in the country. The Industrial output growth rate in the financial 2010-11 reached 8.6 per cent while the manufacturing sector registered a growth rate of 9.1 per cent. The total amount of foreign direct investment (FDI) equity inflows during April 2011- November 2011 stood at US$ 22,835 million. Foreign exchange reserves stood at US$ 293.383 billion for the week ended February 10, 2012.
India is the fourteenth largest exporter and eleventh largest importer in the world. Indian Exports during

2011-12 (April-September) stood at US$ 160.0 billion, recording a higher growth of 52.1 per cent as compared with an increase of 30.0 per cent during the corresponding period of 2010-11. Imports stood at US$ 233.5 billion registered a growth of 32.4 per cent as compared with 37.6 per cent in the preceding year.

Pharmaceuticals
The Indian Pharmaceutical Industry currently tops the chart amongst Indias science -based industries with wide ranging capabilities in the complex field of drug manufacture and technology. The Indian pharmaceutical market is expected to touch US$ 74 billion sales by 2020 from US$ 11 billion now. India's pharmaceutical market grew at 15.7 per cent during December 2011, with growth in key therapy areas, including anti-diabetics, derma and vitamins outperformed the market. India has world renowned drugs. India also has a researchers, which opens discoveries along with joint capacity in producing low cost, high quality bulk and generic vast pool of trained pharmaceutical scientists, doctors and up avenues for joint collaborative research for new drug intellectual property rights (IPRs).